IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer

Documenti analoghi

• Atezolizumab + Chemotherapy for Advanced Non‐Small Cell Lung Cancer in Japanese Clinical Practice (J‐TAIL‐2)
  di: Hiroshige Yoshioka, et al.
  Pubblicazione: (2025)
• Burkholderia vietnamiensis Bacteraemia After Lung Transplantation in a Patient With Diffuse Panbronchiolitis
  di: Taiki Ryo, et al.
  Pubblicazione: (2026)
• Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J‐ TAIL ‐2
  di: Yasushi Goto, et al.
  Pubblicazione: (2026)
• In regards to “Feasibility study of in‐house second‐channel calibration of dual‐channel electrometers using a battery‐powered current source”
  di: Shimizu Morihito
  Pubblicazione: (2026)
• Association between anticipated follow‐up duration and treatment outcomes in anorexia nervosa: Insights from a Japanese medical prison
  di: Wataru Nakagawa, et al.
  Pubblicazione: (2026)